Viridian Therapeutics Inc
NASDAQ:VRDN

Watchlist Manager
Viridian Therapeutics Inc Logo
Viridian Therapeutics Inc
NASDAQ:VRDN
Watchlist
Price: 22.48 USD 0.22% Market Closed
Market Cap: 1.7B USD
Have any thoughts about
Viridian Therapeutics Inc?
Write Note

Viridian Therapeutics Inc
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Viridian Therapeutics Inc
Capital Expenditures Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Viridian Therapeutics Inc
NASDAQ:VRDN
Capital Expenditures
-$552k
CAGR 3-Years
-71%
CAGR 5-Years
-11%
CAGR 10-Years
-49%
Abbvie Inc
NYSE:ABBV
Capital Expenditures
-$888m
CAGR 3-Years
0%
CAGR 5-Years
-12%
CAGR 10-Years
-4%
Gilead Sciences Inc
NASDAQ:GILD
Capital Expenditures
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Capital Expenditures
-$974m
CAGR 3-Years
-8%
CAGR 5-Years
-8%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Capital Expenditures
-$481.8m
CAGR 3-Years
-30%
CAGR 5-Years
-45%
CAGR 10-Years
-25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Capital Expenditures
-$928.1m
CAGR 3-Years
-18%
CAGR 5-Years
-20%
CAGR 10-Years
-13%

See Also

What is Viridian Therapeutics Inc's Capital Expenditures?
Capital Expenditures
-552k USD

Based on the financial report for Jun 30, 2024, Viridian Therapeutics Inc's Capital Expenditures amounts to -552k USD.

What is Viridian Therapeutics Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-49%

Over the last year, the Capital Expenditures growth was 29%. The average annual Capital Expenditures growth rates for Viridian Therapeutics Inc have been -71% over the past three years , -11% over the past five years , and -49% over the past ten years .

Back to Top